AEON News

Get all your AEON Biopharma news in one place.

Jun 10, 2021

AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic Indications

Newport Beach, Calif., June 8, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA)…

Apr 05, 2021

AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia

-Topline data expected in early-2022- Newport Beach, Calif., April 5, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary…

Mar 09, 2021

AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine

-Clinical trial will enroll both episodic and chronic migraine patients- -Protocol utilizes streamlined treatment paradigm with fewer injections- -Topline data expected in mid-2022- Newport Beach, Calif., March 8, 2021 –…

Sep 03, 2020

AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment

-Critical milestone transitions AEON Biopharma to clinical-stage company--Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021--Investment expected to provide funding for clinical programs…

Oct 08, 2019

AEON Biopharma Appoints Chris Carr as Chief Financial Officer and Scott Akamine as General Counsel

Biopharma Firm Continues to Build Industry Leading Management Team; Poised for Next Phase of Growth in Therapeutic Toxin Market NEWPORT BEACH, Calif., October 1, 2019 – AEON Biopharma, an emerging…

Sep 16, 2019

AEON Biopharma Appoints BOTOX® Therapeutic Head as President and Chief Executive Officer

Dynamic Industry Veteran Led Multi-Billion Dollar Therapeutic Neurotoxin Portfolio NEWPORT BEACH, Calif., May 13, 2019 /PRNewswire/ -- ALPHAEON Corporation announced today that its Board of Directors has named Marc Forth as President and Chief Executive…